Alnylam Pharmaceuticals, Inc. (ALNY) is a Biotechnology company in the Healthcare sector, currently trading at $339.41. It has a SharesGrow Score of 60/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ALNY = $569.47 (+67.8% from the current price, the stock appears undervalued). Analyst consensus target is ALNY = $461 (+35.7% upside).
Valuation: ALNY trades at a trailing Price-to-Earnings (P/E) of 137.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.39.
Financials: revenue is $3.7B, +54.8%/yr average growth. Net income is $314M, growing at +103.6%/yr. Net profit margin is 8.4% (thin). Gross margin is 81.8% (-1.9 pp trend).
Balance sheet: total debt is $1.3B against $789M equity (Debt-to-Equity (D/E) ratio 1.62, leveraged). Current ratio is 2.76 (strong liquidity). Debt-to-assets is 25.7%. Total assets: $5.0B.
Analyst outlook: 39 / 52 analysts rate ALNY as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 58/100 (Partial), Growth 100/100 (Pass), Past 25/100 (Fail), Health 33/100 (Fail), Moat 76/100 (Pass), Future 85/100 (Pass), Income 45/100 (Partial).
